Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity.

ABSTRACT: Immunotherapies, such as chimeric antigen receptor T cells, bispecific antibodies, and immune checkpoint inhibitors, have emerged as promising modalities in multiple hematologic malignancies. Despite the excitement surrounding immunotherapy, it is currently not possible to predict which patients will respond. Within solid tumors, the status of the immune microenvironment provides valuable insight regarding potential responses to immune therapies. Much less is known about the immune microenvironment within hematologic malignancies but the characteristics of this environment are likely to serve a similar predictive role. Acute myeloid leukemia (AML) is the most common hematologic malignancy in adults, and only 25% of patients are alive 5 years following their diagnosis. There is evidence tha

SUBMITTER: Lamble AJ 

PROVIDER: S-EPMC6008423 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature